Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2018-07-01
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.
NCT01835678
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
NCT04853615
Linagliptin's Effect on CD34+ Stem Cells
NCT02467478
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
NCT05709444
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
NCT03436693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will be an observational prospective cohort study.
Study population:
Diabetics undergoing any intervention using radiocontrast material for any medical indication in Fayoum universiy hospital will be selected. There will be two arms of the study,each arm will contain 20 patients first arm diabetics on linagelptin, second arm diabetics on other DPP4 inhibitors.
Data collection:
Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI assessment fasting blood glucose,Serum uric acid, urine ACR, eGFR will be done before and after the investigation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
diabetics on linagelptin
Diabetic patients were given linagelptin for blood glucose control
Linagliptin Oral Tablet
Linagliptin for blood glucose control
diabetics on other DPP4 inhibitors
Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
Linagliptin Oral Tablet
Linagliptin for blood glucose control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Linagliptin Oral Tablet
Linagliptin for blood glucose control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Fayoum University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelkawi Hammad
Lecturer of internal medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Usama A Sharafeldin, MD
Role: STUDY_DIRECTOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of medicine Fayoum univesity
Al Fayyum, , Egypt
Fayoum University
Al Fayyum, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fayed A, Hammad AA, Abdulazim DO, Hammad H, Amin M, Elhadidy S, Salem MM, ElAzim IMA, Zsom L, Csongradi E, Soliman KM, Sharaf El Din UA. Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study. Ren Fail. 2023 Dec;45(1):2194434. doi: 10.1080/0886022X.2023.2194434.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCG 4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.